Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

TAIPEI, Taiwan I April 29, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative ...

WHIPPANY, NJ, USA I April 29, 2025 I Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted ...

Proof-of-concept shows mRNA genetic circuitry able to target expression of IL-12 to tumors when systemically delivered ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional ...

VYJUVEK was approved by the FDA in the United States in May 2023 and is also under review for approval by Japan’s Pharmaceuticals and Medical Devices Agency with a decision expected in 2H 2025.

NEW YORK, NY, USA I April 28, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma ...

Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population ...

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...

DARMSTADT, Germany I April 28, 2025 I Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

HONG KONG, China I April 24, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) ...